Andere Sprachen CRISPR Therapeutics AG

Aktien

A2AT0Z

CH0334081137

CRSP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 19.04.2024			% 5 Tage	% 1. Jan.
55,05 ^USD	-1,98 %		-9,26 %	-12,06 %

18.04.	CRISPR THERAPEUTICS AG : Bewertung von Citigroup zum Kaufen erhalten	ZM
17.04.	Crispr Therapeutics Insider verkaufte Aktien im Wert von $1.173.232, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	17.04.
Harvard University: How to realize immense promise of gene editing	17.04.
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	03.04.
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	01.04.
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents	26.03.
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	13.03.
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	21.02.
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	21.02.
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M	21.02.
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10	21.02.
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21.02.
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.02.
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	16.02.
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	15.02.
CRISPR Therapeutics - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	14.02.
CRISPR Therapeutics to Sell About $280 Million of Common Shares	13.02.
CRISPR Therapeutics Announces $280 Million Registered Direct Offering	13.02.
Vertex secures European approval for CRISPR cell therapy	13.02.
CRISPR Therapeutics Secures Conditional Marketing Approval in Europe for Casgevy to Treat Sickle Cell Disease, Transfusion-Dependent Beta Thalassemia	13.02.
European Commission Grants Crispr Therapeutics Conditional Marketing Permit for Casgevy	13.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CRISPR Therapeutics AG

Aktien

A2AT0Z

CH0334081137

CRSP

Andere Sprachen

Filter